Specialty drug and medical device maker Baxter International Inc. said Wednesday it has produced its first commercial batch of Celvapan A/H1N1 and is in discussions to distribute the swine flu vaccine. Celvapan will be delivered to national health authorities that have pandemic agreements with Baxter. The mock-up vaccine was tested in five clinical trials worldwide in at least 1,300 people, and more than 3,500 people were vaccinated during a late-phase study. Trials to evaluate the drug's safety in adults, the elderly and children will begin in August. Baxter started commercial production in June, after the U.S. Centers for Disease Control and Prevention gave the company the strain for testing.
Disclosure No Positions